editorial | Q871232 |
scholarly article | Q13442814 |
P2093 | author name string | Dominik Wolf | |
Janna Rudolph | |||
Kathrin Schönberg | |||
P2860 | cites work | Functions of natural killer cells | Q29614300 |
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis | Q33399980 | ||
JAK Inhibition Impairs NK Cell Function in Myeloproliferative Neoplasms | Q41127061 | ||
Ruxolitinib: the first FDA approved therapy for the treatment of myelofibrosis. | Q53175859 | ||
Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis? | Q54393708 | ||
Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease | Q87635679 | ||
P433 | issue | 8 | |
P304 | page(s) | 677-678 | |
P577 | publication date | 2015-08-31 | |
P1433 | published in | Oncoscience | Q27725796 |
P1476 | title | NK cell modulation by JAK inhibition | |
P478 | volume | 2 |
Search more.